DDInter927 DDInter1063
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).
Levosalbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Beclomethasone dipropionate
Levosalbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Levosalbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Levosalbutamol {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Levosalbutamol may cause a minor interaction that can limit clinical effects when taken with Beclomethasone dipropionate
Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levosalbutamol may lead to a major life threatening interaction when taken with Ribociclib